Table 4 Multivariable analysis of uterine sarcoma patients reporting crude (cHR) and adjusted hazard ratios (aHR) with a 95% Confidence Interval (CI)

Age (years)

  < 50

1

  ≥ 50

1.41 (1.16–2.78)

0.176*

1.36 (0.56–3.40)

0.091

Menstrual status

 Pre-menstrual

1

 Post-menstrual

1.23 (1.09–2.63)

0.081*

1.11 (0.67–2.99)

0.079

Parity

 Parity = 0

1

 Parity ≥ 1

1.76 (0.57–4.07)

0.300

-

-

Tumor size

  < 5 cm

1

  ≥ 5 cm

1.95 (1.07–4.20)

0.020*

1.91 (1.39–2.82)

0.047**

Figo stage

 Stage I

1

 Stage II

3.43 (2.46–5.51)

2.51 (1.20–3.51)

 Stage III

4.55 (2.90–7.52)

0.002*

2.94 (1.43–4.07)

0.015**

 Stage IV

4.24 (2.87–7.38)

2.81 (1.37–3.90)

Grade of tumor

 Well 

1

 Moderate

1.80 (1.12–3.56)

0.044

-

-

 Poor

2.50 (1.91–5.33)

LVI

 Negative

1

 Positive

0.61 (0.26–1.44)

0.273

-

-

Mitotic index

  < 15 per HPF

1

1

  > 15 per HPF

1.58 (1.16–3.63)

0.084*

1.49 (0.97–2.39)

0.052

Lymph node status

 Negative

1

 Positive

2.81 (0.89–6.81)

0.389

-

-